Literature DB >> 26833487

Get the GIST? An overview of gastrointestinal stromal tumours.

G A Watson1, D Kelly2, M Melland-Smith2, J Gleeson2, G McEntee3, C M Kelly2, J A McCaffrey2.   

Abstract

GISTs are the most common mesenchymal neoplasms of the gastrointestinal tract. The last 20 years have been revolutionary in the understanding of these tumours and began with the discovery of c-KIT, a proto oncogene that when mutated forms the molecular basis for the growth and development of these malignancies. Surgery was previously considered to be the only treatment modality in both local and advanced disease, however, the introduction of immunotherapy agents such as tyrosine kinase inhibitors has had profound effects on how we now approach and manage these tumours. These novel agents have significantly reduced the frequency of disease recurrence and dramatically improved survival, and serve as a model for the study of targeted therapies in other solid tumors. We present a review of gastrointestinal stromal tumours and consider the current evidence based detection and management of these unique tumors.

Entities:  

Keywords:  Gastrointestinal stromal tumors (GIST); Imatinib mesylate; Review; c-KIT

Mesh:

Substances:

Year:  2016        PMID: 26833487     DOI: 10.1007/s11845-016-1410-1

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  62 in total

1.  Operative indications for relatively small (2-5 cm) gastrointestinal stromal tumor of the stomach based on analysis of 60 operated cases.

Authors:  Yoshihide Otani; Toshiharu Furukawa; Masashi Yoshida; Yoshiro Saikawa; Norihito Wada; Masakazu Ueda; Tetsuro Kubota; Makio Mukai; Kaori Kameyama; Yoshinori Sugino; Koichiro Kumai; Masaki Kitajima
Journal:  Surgery       Date:  2006-04       Impact factor: 3.982

2.  Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.

Authors:  R P DeMatteo; J J Lewis; D Leung; S S Mudan; J M Woodruff; M F Brennan
Journal:  Ann Surg       Date:  2000-01       Impact factor: 12.969

3.  Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up.

Authors:  Markku Miettinen; Hala Makhlouf; Leslie H Sobin; Jerzy Lasota
Journal:  Am J Surg Pathol       Date:  2006-04       Impact factor: 6.394

4.  Surgical strategy for gastric gastrointestinal stromal tumors: laparoscopic vs. open resection.

Authors:  Junichi Nishimura; Kiyokazu Nakajima; Takeshi Omori; Tsuyoshi Takahashi; Akiko Nishitani; Toshinori Ito; Toshirou Nishida
Journal:  Surg Endosc       Date:  2006-12-16       Impact factor: 4.584

Review 5.  Gastrointestinal stromal tumors--definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis.

Authors:  M Miettinen; J Lasota
Journal:  Virchows Arch       Date:  2001-01       Impact factor: 4.064

Review 6.  Gastrointestinal stromal tumors: current diagnosis, biologic behavior, and management.

Authors:  I Pidhorecky; R T Cheney; W G Kraybill; J F Gibbs
Journal:  Ann Surg Oncol       Date:  2000-10       Impact factor: 5.344

Review 7.  Gastrointestinal stromal tumours.

Authors:  E M Connolly; E Gaffney; J V Reynolds
Journal:  Br J Surg       Date:  2003-10       Impact factor: 6.939

8.  Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors.

Authors:  Katherine A Janeway; Bernadette Liegl; Amy Harlow; Claudia Le; Antonio Perez-Atayde; Harry Kozakewich; Christopher L Corless; Michael C Heinrich; Jonathan A Fletcher
Journal:  Cancer Res       Date:  2007-10-01       Impact factor: 12.701

9.  Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial.

Authors:  Yoon-Koo Kang; Min-Hee Ryu; Changhoon Yoo; Baek-Yeol Ryoo; Hyun Jin Kim; Jong Jin Lee; Byung-Ho Nam; Nikhil Ramaiya; Jyothi Jagannathan; George D Demetri
Journal:  Lancet Oncol       Date:  2013-10-18       Impact factor: 41.316

Review 10.  NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.

Authors:  George D Demetri; Robert S Benjamin; Charles D Blanke; Jean-Yves Blay; Paolo Casali; Haesun Choi; Christopher L Corless; Maria Debiec-Rychter; Ronald P DeMatteo; David S Ettinger; George A Fisher; Christopher D M Fletcher; Alessandro Gronchi; Peter Hohenberger; Miranda Hughes; Heikki Joensuu; Ian Judson; Axel Le Cesne; Robert G Maki; Michael Morse; Alberto S Pappo; Peter W T Pisters; Chandrajit P Raut; Peter Reichardt; Douglas S Tyler; Annick D Van den Abbeele; Margaret von Mehren; Jeffrey D Wayne; John Zalcberg
Journal:  J Natl Compr Canc Netw       Date:  2007-07       Impact factor: 11.908

View more
  6 in total

1.  Gastrointestinal stromal tumor in the fourth portion of the duodenum does not express the CD117: A case report.

Authors:  Marouane Harhar; Abdelhakim Harouachi; Nada Akouh; Abderrahmane Atmani; Houssam Aabdi; Tariq Bouhout; Amal Bennani; Badr Serji; Tijani El Harroudi
Journal:  Ann Med Surg (Lond)       Date:  2022-03-29

2.  Brunner's gland cyst in combination with gastrointestinal stromal tumor: A case report.

Authors:  Xiqian Huo; Jishu Wei; Xinchun Liu; Junli Wu; Wentao Gao; Qiang Li; Kuirong Jiang; Cuncai Dai; Y I Miao
Journal:  Oncol Lett       Date:  2016-03-29       Impact factor: 2.967

Review 3.  Translating Knowledge About the Immune Microenvironment of Gastrointestinal Stromal Tumors into Effective Clinical Strategies.

Authors:  Jomjit Chantharasamee; Jacob J Adashek; Karlton Wong; Mark A Eckardt; Bartosz Chmielowski; Sarah Dry; Fritz C Eilber; Arun S Singh
Journal:  Curr Treat Options Oncol       Date:  2021-01-05

4.  Gastrointestinal Bleeding Is an Independent Risk Factor for Poor Prognosis in GIST Patients.

Authors:  Qi Liu; Yuji Li; Ming Dong; Fanmin Kong; Qi Dong
Journal:  Biomed Res Int       Date:  2017-05-15       Impact factor: 3.411

5.  BDNF expression in GISTs predicts poor prognosis when associated with PD-L1 positive tumor-infiltrating lymphocytes.

Authors:  Guang-Ang Tian; Wen-Ting Xu; Yue Sun; Jin Wang; Qing Ke; Meng-Jiao Yuan; Jin-Jin Wang; Chun Zhuang; Qian Gong
Journal:  Oncoimmunology       Date:  2021-11-14       Impact factor: 8.110

6.  A Case Report of Multiple Gastrointestinal Stromal Tumors: Imaging Findings, Surgical Approach, and Review of the Literature.

Authors:  Mariarita Tarallo; Cristina Carruezzo; Filippo Maria Dentice Di Accadia; Antonella Del Gaudio; Damiano Caruso; Michela Polici; Daniele Crocetti; Umberto Costi; Andrea Polistena; Francesco Panzuto; Andrea Laghi; Giuseppe Cavallaro; Enrico Fiori
Journal:  Front Surg       Date:  2022-05-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.